title: Importance of carbohydrate in the interaction of Tamm-Horsfall protein with complement 1q and inhibition of classical complement activation.
abstract: Tamm-Horsfall protein (THP) binds strongly to complement 1q (C1q), a key component of the classical complement pathway. The goals of this study were to determine whether THP altered the activation of the classical complement pathway and whether the carbohydrate portion of THP was involved in this glycoprotein's binding to C1q and alteration of complement activation. The ability of THP to prevent complement activation in diluted serum or plasma incubated at 37 degrees C was assessed using both a haemolytic assay with antibody-sensitized sheep RBC and a C4d ELISA. Both these methods showed that THP inhibited activation of the classical complement pathway in a dose-dependent manner. Glycosidases were used to remove most of the carbohydrate from THP. This partially deglycosylated THP bound human IgG with a higher affinity (KD1 = 1.4 nmol/L; KD2 = 0.31 micromol/L) than did intact THP (KD1 = 33.4 nmol/L; KD2 = 31.0 micromol/L). An ELISA showed that removal of carbohydrate from THP reduced, but did not eliminate, the ability of this protein to inhibit binding of C1q to intact THP. Haemolysis assays using antibody-sensitized sheep RBC showed that removal of THP carbohydrate eliminated the ability of THP to protect against complement activation. In conclusion, THP inhibited the activation of the classical complement pathway that occurred in diluted serum or plasma. The carbohydrate moieties of THP appeared to be important in this inhibitory activity.
authors.affiliation: Department of Anatomy, A.T. Still University of Health Sciences, Kirksville College of Osteopathic Medicine, Kirksville, Missouri 63501, USA. drhodes@atsu.edu
authors.forename: Diana C J
authors.initials: DC
authors.lastname: Rhodes
mesh_terms: D015922:Complement C1q / Q000276:immunology / Q000378:metabolism*; D015935:Complement C4b / Q000276:immunology / Q000378:metabolism; D051056:Complement Inactivating Agents / Q000378:metabolism / Q000494:pharmacology*; D003171:Complement Pathway, Classical / Q000187:drug effects* / Q000276:immunology; D003165:Complement System Proteins / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology / Q000378:metabolism; D009088:Mucoproteins / Q000378:metabolism* / Q000494:pharmacology* / Q000652:urine; D010446:Peptide Fragments / Q000276:immunology / Q000378:metabolism; D011485:Protein Binding; D013329:Structure-Activity Relationship; D058949:Uromodulin
chemical_list: D051056:Complement Inactivating Agents; D007074:Immunoglobulin G; D009088:Mucoproteins; D010446:Peptide Fragments; C548612:UMOD protein, human; D058949:Uromodulin; D015922:Complement C1q; D015935:Complement C4b; C032261:complement C4d; D003165:Complement System Proteins